From July 8-10, the 340B Coalition held its biannual conference for 340B hospitals, grantee clinics, and others active in the 340B space.Figure 1: 340B Coalition 2024 Summer Conference Attendee Breakd
Transportation barriers, such as the distance a patient must travel to receive care, can limit healthcare access. Barriers to healthcare access might lead to missed appointments, delayed care or delayed medication use, and poor management of chronic illnesses, all leading to worse health outcomes.1
The Food and Drug Administration (FDA) defines an orphan drug in the 1984 Orphan Drug Act (ODA) as a drug used to treat, prevent, or diagnose a rare disease or condition that affects fewer than 200,000 people in the United States.1 The ACA and the subsequent Health Care and Education Reconciliation
Each quarter we provide a snapshot of registration trends in the 340B program as reflected in the HRSA OPAIS database and provide insights into specific trends of note. Although the underlying data is
The Food and Drug Administration (FDA) defines an orphan drug in the 1984 Orphan Drug Act (ODA) as a drug used to treat, prevent, or diagnose a rare disease or condition that affects fewer than 200,00
340B Replenishment: BackgroundHistorically, pharmacies and covered entities have relied on the physical “replenishment” model to operationalize contract pharmacy transactions. Under 340B replenishment